Other Deals
Lupin spins out two cancer drugs into US-based Kaveri Therapeutics
BSE Announcement Business Line
Publicly listed Lupin has spun out two of its oncology drug programmes to a newly formed US-based venture, Kaveri Therapeutics, in exchange for an 82.2 per cent equity stake valued at $1.6 million. As part of the deal, Lupin will provide seed funding to the new entity and has received 332,000 common shares.Kaveri Therapeutics is a clinical-stage oncology firm incorporated in Delaware on May 20, 2026, that focuses on solid tumors including lung, pancreatic, ovarian, and CNS-related cancers. The firm is led by CEO Kristi Jones and Chief Medical Officer Dr. Robert Pierce. It plans to seek additional capital to support global clinical trials for the two acquired programmes.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
